GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Gross Profit

MAIA (MAIA Biotechnology) Gross Profit : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Gross Profit?

MAIA Biotechnology's gross profit for the three months ended in Jun. 2024 was $0.00 Mil. MAIA Biotechnology's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. MAIA Biotechnology's gross profit for the three months ended in Jun. 2024 was $0.00 Mil. MAIA Biotechnology's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, MAIA Biotechnology's Gross Margin % for the quarter that ended in Jun. 2024 was N/A%.

MAIA Biotechnology had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


MAIA Biotechnology Gross Profit Historical Data

The historical data trend for MAIA Biotechnology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Gross Profit Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross Profit
- - - -

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MAIA Biotechnology's Gross Profit

For the Biotechnology subindustry, MAIA Biotechnology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Gross Profit distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's Gross Profit falls into.



MAIA Biotechnology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

MAIA Biotechnology's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

MAIA Biotechnology's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

MAIA Biotechnology's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MAIA Biotechnology  (AMEX:MAIA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MAIA Biotechnology had a gross margin of N/A% for the quarter that ended in Jun. 2024 => No sustainable competitive advantage


MAIA Biotechnology Gross Profit Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606